Welcome to our dedicated page for Avinger news (Ticker: AVGR), a resource for investors and traders seeking the latest updates and insights on Avinger stock.
Avinger, Inc. (NASDAQ: AVGR) is a commercial-stage medical device company committed to transforming the treatment of Peripheral Artery Disease (PAD) through innovative, image-guided, catheter-based systems. Founded and headquartered in Redwood City, California, Avinger designs, manufactures, and sells its proprietary Lumivascular platform, which includes the Lightbox imaging console, the Ocelot family of catheters for penetrating chronic total occlusions (CTOs), and the Pantheris family of atherectomy devices for removing arterial plaque.
Avinger's mission is to significantly improve clinical outcomes for PAD patients by offering precision and real-time imaging that enhances both diagnosis and treatment. The company's groundbreaking products are developed to address the needs of over 200 million PAD patients worldwide.
Key highlights of Avinger's product lineup include:
- Lightbox Imaging Console: An advanced system providing real-time intravascular imaging.
- Ocelot Catheters: Designed for crossing chronic total occlusions with precision.
- Pantheris Atherectomy Devices: The first-ever image-guided devices for the removal of arterial plaque.
- Tigereye ST CTO-Crossing Catheter: Launched to significant market enthusiasm, providing enhanced performance for complex procedures.
Recent financial disclosures indicate that Avinger is actively expanding its commercial footprint. The company recently reported financial results for the third quarter of 2023, with total revenue of $1.8 million and notable developments including the launch of the Tigereye ST and Pantheris LV systems. Despite a net loss of $4.5 million, Avinger continues to invest in product development and sales expansion, primarily in the United States.
A key strategic move for Avinger has been the newly formed partnership with Zylox-Tonbridge, a leading Chinese medical device company. This collaboration is set to provide up to $15 million in equity funding and facilitate Avinger's entry into the Greater China market. The partnership also aims to enhance manufacturing efficiency and explore new revenue opportunities through product distribution in the U.S. and Germany.
In addition to advancing its peripheral products, Avinger is making strides in the coronary space. The company is developing a new image-guided system for treating coronary artery disease (CAD), with plans to file an Investigational Device Exemption (IDE) application with the FDA by mid-2024. This development emphasizes Avinger's commitment to addressing unmet medical needs across both peripheral and coronary segments.
For the most current updates and detailed information on Avinger, Inc., their products, financial reports, and more, please visit their official website at www.avinger.com.
FAQ
What is the current stock price of Avinger (AVGR)?
What is the market cap of Avinger (AVGR)?
What does Avinger, Inc. do?
What are Avinger's main products?
Where is Avinger, Inc. based?
How is Avinger expanding its market presence?
What recent financial results has Avinger reported?
What is the significance of Avinger's partnership with Zylox-Tonbridge?
Is Avinger developing any new products?
What is Avinger's mission?
How can I get more information about Avinger, Inc.?